• Citer

An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors

par Awada, Ahmad ;Campone, Mario;Varga, Andrea;Aftimos, Philippe ;Frenel, Jean Sébastien;Bahleda, Rastilav;Gombos, Andrea ;Bourbouloux, Emmanuelle;Soria, Jean-Charles
Référence Anti-cancer drugs, 27, 4, page (342-348)
Publication Publié, 2016-04

Article révisé par les pairs

• Détails
• Contenu

Titre:	An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors
Auteur:	Awada, Ahmad; Campone, Mario; Varga, Andrea; Aftimos, Philippe; Frenel, Jean Sébastien; Bahleda, Rastilav; Gombos, Andrea; Bourbouloux, Emmanuelle; Soria, Jean-Charles
Informations sur la publication:	Anti-cancer drugs, 27, 4, page (342-348)
Statut de publication:	Publié, 2016-04
Sujet CREF:	Cancérologie
	Pharmacologie
Mots-clés:	CEP-8983
	Chemotherapy regimen
	Poly (ADP-ribose) polymerase-1 inhibitor
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0959-4973
	info:doi/10.1097/CAD.0000000000000336
	info:scp/84954563985